Placebo-Controlled Trials in Schizophrenia J Clin Med Res • 2009;1(3):132-136 cebo-controlled trials in schizophrenia. Am J Psychiatry 2003;160(2):356-362. 17. Quitkin FM. Placebos, drug effects, and study design: a clinician’s guide. Am J Psychiatry 1999;156(6):829- 836. 18. Warner R. The prevention of schizophrenia: what in- terventions are safe and effective? Schizophr Bull 2001;27(4):551-562. 19. Lieberman JA, Perkins D, Belger A, Chakos M, Jar- skog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, patho- physiology, and therapeutic approaches. Biol Psychiatry 2001;50(11):884-897. 20. Curson DA, Hirsch SR, Platt SD, Bamber RW, Barnes TR. Does short term placebo treatment of chronic schizophrenia produce long term harm? Br Med J (Clin Res Ed) 1986;293(6549):726-728. 21. Labelle A, Boulay LJ, Lapierre YD. Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry 1999;44(9):887-892. 22. Roberts LW. Ethics and mental illness research. Psychi- atr Clin North Am 2002;25(3):525-545. 23. Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary? Schizophr Res 1999;35(3):211-218; discussion 227-236. 24. Appelbaum PS. Use of placebo-control in clinical trials in accordance with the Declaration of Helsinki. 3rd In- ternational Conference on Psychiatry, Law, and Ethics, Eilat, Israel, 2004. 25. Tamir O, Shemer J. Clinical trials – historical devel- opmental, regulation and updated data. Harefuah 2004;143: 232-235 [Hebrew]. 26. European Agency for the Evaluation of Medicinal Products. ICH Topic E 6 Guideline for Good Clinical Practice. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). London, 2002. 136 Articles © The authors, Journal compilation © J Clin Med Res and Elmer Press™, www.jocmr.org